Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Seres Therapeutics Q3 EPS $0.94 Beats $0.67 Estimate, Sales $351.000K Miss $5.875M Estimate

Author: Benzinga Newsdesk | November 05, 2025 07:04am
Seres Therapeutics (NASDAQ:MCRB) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.67 by 40.3 percent. This is a 114.24 percent increase over losses of $(6.60) per share from the same period last year. The company reported quarterly sales of $351.000 thousand which missed the analyst consensus estimate of $5.875 million by 94.03 percent.

Posted In: MCRB


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist